ClinicalTrials.gg
Active, not recruitingNCT07850713Updated Sep 30, 2026

Comparison of the Effect of Allopurinol Versus Febuxostat on Serum Uric Acid in Patients With Chronic Kidney Disease Associated With Hyperuricemia

An interventional study of Febuxostat and allopurinol in Hyperuricemia and Renal Insufficiency, Chronic, sponsored by Nishtar Medical University. Active, not recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Nishtar Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled May 2026, registered Sep 2026).
Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies testing febuxostat in Hyperuricemia — 2 open to participants now, 4 under way, none of them phase 3. Febuxostat · Hyperuricemia.

Enrollment
19th of 26
66 · median 111
Started
2026
with 2 others
No phase
6 of 26
none open now
Registered
26th of 26
by date

Among the 26 studies testing febuxostat in Hyperuricemia, this one is the 19th largest by enrollment, is one of 3 that started in 2026, is one of 6 with no phase, and was the 26th registered.

Hyperuricemia

240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.

Browse Hyperuricemia studies →

Open to participants now

2 of the 26 studies testing febuxostat in Hyperuricemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About febuxostat

Febuxostat: first FDA approval 2009 (ULORIC), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Hyperuricemia studies recruiting now, 9 (30%) set no upper age limit and 13 (43%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing febuxostat in Hyperuricemia, or all of them as a file.
02

Study summary

This randomized study was designed to compare how well allopurinol and febuxostat lowered blood uric acid in adults with chronic kidney disease and high uric acid levels. It was planned to include 66 participants, aged 18 to 65 years, with stage 3 to 5 chronic kidney disease. Participants were to be assigned to receive either febuxostat 40 mg daily or allopurinol at a dose adjusted for their level of kidney function. Treatment was planned for eight weeks, with follow-up visits at weeks 4 and 8.

The researchers hypothesized that the two medicines would differ in their effects after eight weeks. The main measure was the proportion of participants whose uric acid level reached below 6.0 mg/dL. Changes in uric acid levels and estimated kidney function were also to be compared.

03

Conditions studied

  • Hyperuricemia
  • Renal Insufficiency, Chronic

Keywords

  • Chronic kidney disease stages 3 to 5
  • Serum uric acid
  • Allopurinol
  • Febuxostat
  • Estimated glomerular filtration rate
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Adult patients of either gender between the ages of 18 and 65.
  • According to operational standards, chronic kidney disease was diagnosed in stages 3 to 5.
  • Hyperuricemia at baseline as per operational definition.
  • Clinically stable chronic kidney disease without acute deterioration within the preceding 4 weeks.
  • Not receiving febuxostat or allopurinol within the preceding 4 weeks, or suitable for protocol-defined washout if applicable.

Exclusion Criteria:

Exclusion criteria

  • Acute kidney injury or recent rapidly progressive decline in kidney function within the last 4 weeks.
  • Maintenance hemodialysis or peritoneal dialysis, or planned initiation of renal replacement therapy within the next 8 weeks.
  • History of kidney transplantation.
  • Known or prior severe adverse reaction to allopurinol or febuxostat, including suspected allopurinol hypersensitivity syndrome.
  • Severe hepatic impairment or baseline or aspartate aminotransferase more than 3 times the .
  • Active symptomatic gout flare at enrollment requiring immediate anti-inflammatory escalation that would confound urate assessment.
  • Use of other urate-lowering therapies within the last 4 weeks, such as probenecid, benzbromarone, pegloticase, rasburicase, or high-dose uricosurics.
  • Current chemotherapy, active with anticipated short-term clinical instability, or conditions associated with marked urate overproduction that require specialized management.
  • Uncontrolled heart failure or recent major cardiovascular event within the last 3 months, if local protocol mandates cardiovascular risk restriction for febuxostat initiation.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Group A - Febuxostat

    Participants assigned to this group were to receive febuxostat 40 mg orally once daily for 8 weeks.

    Drug: Febuxostat

  • Active comparator
    Group B - Allopurinol

    Participants assigned to this group were to receive allopurinol orally for 8 weeks, with the starting dose determined by chronic kidney disease stage.

    Drug: allopurinol

Interventions

  • 40 mg orally once daily for 8 weeks.

  • Stage 3: 100 mg once daily; stage 4: 50 mg once daily; stage 5: 50 mg once daily or every other day, according to the study protocol.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Serum Uric Acid Below 6.0 mg/dL

    The percentage of participants in each treatment group whose serum uric acid level was below 6.0 mg/dL at the 8-week assessment.

    Time frame: 8 weeks after treatment initiation

Secondary outcomes

  1. Change in Serum Uric Acid From Baseline to 8 Weeks

    The mean change in serum uric acid in each treatment group, calculated as the 8-week value minus the baseline value and expressed in mg/dL.

    Time frame: Baseline and 8 weeks after treatment initiation

  2. Change in Estimated Glomerular Filtration Rate From Baseline to 8 Weeks

    The mean change in estimated glomerular filtration rate in each treatment group, calculated as the 8-week value minus the baseline value and expressed in mL/min/1.73 m².

    Time frame: Baseline and 8 weeks after treatment initiation

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Nov 2026, 5 months after the start.

Of 26 interventional studies with no phase under Hyperuricemia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 34. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartActual
May 13, 2026
Primary completionEst.
Nov 12, 2026
CompletionEst.
Nov 12, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07850713
Lead sponsor
Nishtar Medical University
Responsible party
Shazia Parveen (Principal Investigator, Nishtar Medical University) — Principal investigator
First posted
Sep 30, 2026
Start date
May 13, 2026
Primary completion
Nov 12, 2026 (estimated)
Completion
Nov 12, 2026 (estimated)
Last update
Sep 30, 2026

Study contacts

Naveed Riaz
principal investigator · Nishtar Hospital Multan

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Febuxostat

Start the discussion